MiMedx Group Net Income
| MDXG Stock | USD 5.12 0.03 0.59% |
As of the 14th of February 2026, MiMedx secures the mean deviation of 1.72, and Risk Adjusted Performance of (0.22). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MiMedx Group, as well as the relationship between them. Please verify MiMedx Group information ratio and skewness to decide if MiMedx Group is priced some-what accurately, providing market reflects its recent price of 5.12 per share. Given that MiMedx Group has information ratio of (0.31), we recommend you to check MiMedx's last-minute market performance to make sure the company can sustain itself at a future point.
MiMedx Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.62 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 48.3 M | 50.7 M | |
| Net Income From Continuing Ops | 37.8 M | 39.7 M | |
| Net Loss | -33.1 M | -31.4 M | |
| Net Income Per Share | 0.26 | 0.27 | |
| Net Income Per E B T | 0.85 | 0.81 |
MiMedx | Net Income | Build AI portfolio with MiMedx Stock |
The Net Income trend for MiMedx Group offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether MiMedx is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest MiMedx's Net Income Growth Pattern
Below is the plot of the Net Income of MiMedx Group over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in MiMedx Group financial statement analysis. It represents the amount of money remaining after all of MiMedx Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is MiMedx's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MiMedx's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 42 M | 10 Years Trend |
|
Net Income |
| Timeline |
MiMedx Net Income Regression Statistics
| Arithmetic Mean | 8,735,461 | |
| Coefficient Of Variation | 412.36 | |
| Mean Deviation | 29,983,478 | |
| Median | (16,738) | |
| Standard Deviation | 36,021,889 | |
| Sample Variance | 1297.6T | |
| Range | 116.7M | |
| R-Value | 0.34 | |
| Mean Square Error | 1223T | |
| R-Squared | 0.12 | |
| Significance | 0.18 | |
| Slope | 2,433,441 | |
| Total Sum of Squares | 20761.2T |
MiMedx Net Income History
Other Fundumenentals of MiMedx Group
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
MiMedx Net Income component correlations
MiMedx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for MiMedx is extremely important. It helps to project a fair market value of MiMedx Stock properly, considering its historical fundamentals such as Net Income. Since MiMedx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MiMedx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MiMedx's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does MiMedx have expansion opportunities? Factors like these will boost the valuation of MiMedx. Expected growth trajectory for MiMedx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating MiMedx demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 1.138 | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that MiMedx's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MiMedx represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MiMedx's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
MiMedx 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MiMedx's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MiMedx.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in MiMedx on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding MiMedx Group or generate 0.0% return on investment in MiMedx over 90 days. MiMedx is related to or competes with Innoviva, Sana Biotechnology, Dianthus Therapeutics, Nektar Therapeutics, ATAI Life, Rapport Therapeutics, and Taysha Gene. MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare More
MiMedx Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MiMedx's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MiMedx Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.31) | |||
| Maximum Drawdown | 10.23 | |||
| Value At Risk | (3.79) | |||
| Potential Upside | 2.82 |
MiMedx Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MiMedx's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MiMedx's standard deviation. In reality, there are many statistical measures that can use MiMedx historical prices to predict the future MiMedx's volatility.| Risk Adjusted Performance | (0.22) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.77) | |||
| Treynor Ratio | (0.72) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MiMedx's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
MiMedx February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.22) | |||
| Market Risk Adjusted Performance | (0.71) | |||
| Mean Deviation | 1.72 | |||
| Coefficient Of Variation | (361.16) | |||
| Standard Deviation | 2.15 | |||
| Variance | 4.62 | |||
| Information Ratio | (0.31) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.77) | |||
| Treynor Ratio | (0.72) | |||
| Maximum Drawdown | 10.23 | |||
| Value At Risk | (3.79) | |||
| Potential Upside | 2.82 | |||
| Skewness | (0.05) | |||
| Kurtosis | (0.20) |
MiMedx Group Backtested Returns
MiMedx Group has Sharpe Ratio of -0.23, which conveys that the firm had a -0.23 % return per unit of volatility over the last 3 months. MiMedx exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify MiMedx's mean deviation of 1.72, and Risk Adjusted Performance of (0.22) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.85, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MiMedx's returns are expected to increase less than the market. However, during the bear market, the loss of holding MiMedx is expected to be smaller as well. At this point, MiMedx Group has a negative expected return of -0.51%. Please make sure to verify MiMedx's jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if MiMedx Group performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.56 |
Good reverse predictability
MiMedx Group has good reverse predictability. Overlapping area represents the amount of predictability between MiMedx time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MiMedx Group price movement. The serial correlation of -0.56 indicates that roughly 56.0% of current MiMedx price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.56 | |
| Spearman Rank Test | -0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.28 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
MiMedx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, MiMedx Group reported net income of 42 M. This is 87.69% lower than that of the Biotechnology sector and 40.04% lower than that of the Health Care industry. The net income for all United States stocks is 92.64% higher than that of the company.
MiMedx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MiMedx's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MiMedx could also be used in its relative valuation, which is a method of valuing MiMedx by comparing valuation metrics of similar companies.MiMedx is currently under evaluation in net income category among its peers.
MiMedx Current Valuation Drivers
We derive many important indicators used in calculating different scores of MiMedx from analyzing MiMedx's financial statements. These drivers represent accounts that assess MiMedx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of MiMedx's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 983.0M | 666.5M | 313.9M | 1.0B | 919.5M | 466.7M | |
| Enterprise Value | 939.0M | 632.7M | 300.4M | 987.8M | 889.0M | 449.7M |
MiMedx ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MiMedx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MiMedx's managers, analysts, and investors.Environmental | Governance | Social |
MiMedx Institutional Holders
Institutional Holdings refers to the ownership stake in MiMedx that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of MiMedx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MiMedx's value.| Shares | First Light Asset Management, Llc | 2025-06-30 | 1.9 M | Millennium Management Llc | 2025-06-30 | 1.7 M | Qube Research & Technologies | 2025-06-30 | 1.2 M | Harbor Capital Advisors Inc | 2025-06-30 | 1.2 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.1 M | Northern Trust Corp | 2025-06-30 | 1.1 M | Meros Investment Management, Lp | 2025-06-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.1 M | Royal Bank Of Canada | 2025-06-30 | 938.7 K | Essex Woodlands Health Ventures | 2025-06-30 | 28.2 M | Blackrock Inc | 2025-06-30 | 11.5 M |
MiMedx Fundamentals
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 637.38 M | ||||
| Shares Outstanding | 148.1 M | ||||
| Shares Owned By Insiders | 1.65 % | ||||
| Shares Owned By Institutions | 72.30 % | ||||
| Number Of Shares Shorted | 7.14 M | ||||
| Price To Earning | 23.73 X | ||||
| Price To Book | 3.19 X | ||||
| Price To Sales | 1.93 X | ||||
| Revenue | 348.88 M | ||||
| Gross Profit | 322.58 M | ||||
| EBITDA | 65.35 M | ||||
| Net Income | 42 M | ||||
| Cash And Equivalents | 72.5 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 24.84 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 3.53 X | ||||
| Book Value Per Share | 1.61 X | ||||
| Cash Flow From Operations | 66.2 M | ||||
| Short Ratio | 7.02 X | ||||
| Earnings Per Share | 0.27 X | ||||
| Price To Earnings To Growth | 2.97 X | ||||
| Target Price | 10.4 | ||||
| Number Of Employees | 837 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 758.28 M | ||||
| Total Asset | 263.92 M | ||||
| Retained Earnings | (91.26 M) | ||||
| Working Capital | 146.29 M | ||||
| Current Asset | 96.31 M | ||||
| Current Liabilities | 26.78 M | ||||
| Net Asset | 263.92 M |
About MiMedx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MiMedx Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MiMedx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MiMedx Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Can Biotechnology industry sustain growth momentum? Does MiMedx have expansion opportunities? Factors like these will boost the valuation of MiMedx. Expected growth trajectory for MiMedx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating MiMedx demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 1.138 | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that MiMedx's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MiMedx represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MiMedx's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.